Navigation Links
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
Date:4/22/2009

iffer materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                       Media
    info@peregrineinc.com                           Barbara Lindheim
    (800) 987-8256                                  (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  CytRx Corporation (CYTR), a biopharmaceutical ... reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical ... in the early months of 2015, including the ... of aldoxorubicin in patients with soft tissue sarcoma, ...
(Date:5/1/2015)... , May 1, 2015  Boston Scientific Corporation ... its continued business momentum and long-term growth strategies at ... New York City . President and Chief ... unique opportunities the company has to bring forward meaningful ... growing markets and deliver shareholder value. ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... 05, 2007 /PRNewswire/ -- Results from,the primary ... study showed that 77 percent of treatment-experienced ... tablets with,100 mg ritonavir (PREZISTA/r) twice daily, ... (ARV) agents, reached a,plasma viral load of ...
... Cobalis Corp.,(OTCBB:CLSC), a pharmaceutical development company specializing ... two Phase III clinical trials for its ... severe,seasonal allergic rhinitis, commonly known as hay ... in both placebo and,PreHistin-treated patient groups, thereby ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5
(Date:5/1/2015)... CA (PRWEB) May 01, 2015 TROY ... the Cerner Southeast Regional User Group (RUG) Conference in ... Cerner Southeast Regional User Group Conference provides a forum ... vendors who support all aspects of electronic medical record ... of Cerner software applications. , In addition to sponsoring ...
(Date:5/1/2015)... 01, 2015 Hope For The Warriors® ... Hope For The Warriors® and military families. All American ... Hope For The Warriors®, a national nonprofit dedicated to ... and restoring hope for our service members and our ... American Ford collected and matched small autograph fee from ...
(Date:5/1/2015)... The fields of genetics and genomics, the ... genes with one another and the environment, is rapidly ... LabRoots, the premier producer of interactive virtual events for ... its annual conference spotlighting the recent advances in Genetics ... Genomics 2015 , a two-day event presented entirely online ...
(Date:5/1/2015)... Washington, D.C. (PRWEB) May 01, 2015 Today ... campaign is expanding its fundraising efforts to help protect the ... the first new program support country added since Girl Up ... Day fundraising campaign aimed at supporting adolescent girls in the ... years Girl Up has supported the advancement of adolescent girls ...
(Date:5/1/2015)... 2015 Digital technology and Wi-Fi-enabled medical ... between prenatal appointments, a preliminary study has ... sample of low-risk pregnant women, will be presented as ... Medical Faculty Associates at the 2015 American Congress of ... May 2-6. The digital technology used was developed by ...
Breaking Medicine News(10 mins):Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3Health News:United Nations Foundation’s Girl Up Campaign Announces New Funding Initiative to Support Adolescent Girls in India 2Health News:United Nations Foundation’s Girl Up Campaign Announces New Funding Initiative to Support Adolescent Girls in India 3Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 3
... The Duke Human Vaccine Institute today announced a ... Diagnostics to enable the rapid development of a ... pandemic virus threat such as pandemic influenza. The ... utilize resources of the National Institute of Allergy ...
... 14 (HealthDay News) -- Parents who say "um" and "uh" ... they,re actually helping the children learn language more efficiently, according ... 30 months found that older children paid more attention to ... the item stumbled and said, "Look at the, uh..." ...
... More intensive or family-based HIV prevention interventions may ... and stop engaging in risky sexual behavior, say researchers ... Juvenile offenders are at increased risk for contracting HIV ... have sex at earlier ages, have more sexual partners, ...
... 2011 An international consortium of scientists, including ... that the "one-size fits all" strategy of uniformly ... for patients with high on-treatment platelet reactivity does ... and stent thrombosis after percutaneous coronary intervention (PCI). ...
... French and Spanish . , A ... Antonio Campos and Miguel Alaminos (histologists), Mara del Mar Prez, ... the ophthalmologist Miguel Gonzlez Andrades, University Hospital San Cecilio, Granada, ... extracted pig corneal cells and replaced them with human stem ...
... , THURSDAY, April 14 (HealthDay News) -- Home safety ... small children, according to a new study. Researchers ... groups of families with newborns. One set of families ... homes, including stairway gates, cabinet locks, electrical outlet covers, ...
Cached Medicine News:Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3Health News:Better HIV prevention interventions needed for juvenile offenders 2Health News:Better HIV prevention interventions needed for juvenile offenders 3Health News:Antiplatelets: 1 person, 1 dose? 2Health News:With Safety Devices in Place, Kids' Injuries Decline: Study 2
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: